Min Xue

Min Xue


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
MYMusan Yan
Musan Yan
YWYuewei Wang
Yuewei Wang
LNLiyuan Niu
Liyuan Niu
SWShaoying Wang
Shaoying Wang
HYHaichu Yu
Haichu Yu
CLCHANGJIANG LI
CHANGJIANG LI

10 January 2026 in Natural Products and Bioprospecting
Verified
Journal Article
Open access
PDF file
LNLiyuan Niu
Liyuan Niu
CLChuanfeng Liu
Chuanfeng Liu
SWShaoying Wang
Shaoying Wang
QYQikai Yin
Qikai Yin
SLShiping Lin
Shiping Lin
YWYuewei Wang
Yuewei Wang
Thrombosis pathogenesis is closely linked to dysregulated lipid metabolism and inflammatory processes. However, the direct regulatory role of mevalonate pathway within the coagulation cascade is still not well understood. This study aimed to elucidate the regulatory effects of mevalonic acid (MVA) on the coagulation system. The effects of MVA on coagulation were measured by recalcification. Enzymatic kinetic analysis and natural substrate hydrolysis assays were performed to identify the coagulation target of MVA. Mice bleeding and thrombosis models were applied to evaluate the effects of MVA administration on hemostasis and thrombosis. Our current study reveals that MVA significantly accelerates plasma coagulation through potentiating the procoagulant activity of FXa, without influencing the platelet aggregation. Studies showed that MVA administration substantially shortened activated partial thromboplastin time, prothrombin time, and reduced bleeding time in both tail bleeding and saphenous vein injury models. Furthermore, using ferric chloride-induced thrombosis, deep vein thrombosis and cerebral infarction models, we observed that MVA markedly potentiated thrombus formation and stroke. Our findings establish for the first time that MVA directly regulates FXa procoagulant activity, while also suggesting potential crosstalk between lipid metabolic pathways and inflammatory signaling in coagulation modulation. These results provide novel mechanistic insights into coagulation abnormalities associated with metabolic disorders such as atherosclerosis and diabetes, highlighting the mevalonate pathway as a potential therapeutic target for thrombotic complications. Graphical Abstract

15 April 2026 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
YWYuewei Wang
Yuewei Wang
QYQikai Yin
Qikai Yin
XJXin Jiang
Xin Jiang
WLWenshuo Li
Wenshuo Li
MYMusan Yan
Musan Yan
XTXiaopeng Tang
Xiaopeng Tang
The complex interplay between inflammation and coagulation drives thromboinflammatory disorders. While previous studies have shown that interleukin-1β (IL-1β) can induce a hypercoagulable state in response to tissue hypoxia and inflammation, the specific mechanisms of its action on the coagulation cascade remain unclear. Here, we demonstrate that IL-1β directly potentiates key coagulation factors (FXIa, FXa, thrombin, and kallikrein) to accelerate thrombosis. Mechanistically, IL-1β enhances FXIa enzymatic activity through specific binding to its exosite domain. Additionally, we established an IL-1β-FXIa interaction model, based on which the inhibitory peptide QK10 was derived to specifically disrupt their interaction interface and effectively block IL-1β's potentiation of FXIa. Critically, in multiple thrombosis models, QK10 exhibited significant antithrombotic efficacy at doses equal to low molecular weight heparin (LMWH). Notably, bleeding assays revealed a significantly lower bleeding risk with QK10 compared to LMWH. Notably, QK10 also demonstrated promising anti-stroke efficacy in ischemic stroke models. Taken together, these findings establish QK10 as a viable therapeutic candidate that targets the IL-1β-FXIa prothrombotic axis for disruption, features enhanced safety, and offers a new approach to treating thrombo-inflammatory conditions, including ischemic stroke.

14 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWShaoying Wang
Shaoying Wang
MXMin Xue
Min Xue
MYMusan Yan
Musan Yan
CLChuanfeng Liu
Chuanfeng Liu
MWMengmeng Wang
Mengmeng Wang
XTXiaopeng Tang
Xiaopeng Tang
Hypertension has paradoxical prothrombotic-hemorrhagic predisposition toward cerebral infarction and intracerebral hemorrhage (ICH), but the mechanism remains poorly understood. We observed Angiotensin II (Ang II) inhibited coagulation by activating antithrombin through heparin-like acceleration of antithrombin-thrombin interaction. Ang II allosterically modulates the 386-397 loop of antithrombin to enhance thrombin inhibition. In vivo, single injection of Ang II inhibited coagulation, alleviating thrombosis and aggravating ICH. Conversely, anti-Ang II monoclonal antibody promoted coagulation, aggravating thrombus formation and alleviating ICH. Notably, the blockage or deficiency of Ang II receptor had no significant effect on the alleviated thrombus formation or aggravated hemorrhage elicited by Ang II, suggesting the phenotypes were independent of Ang II receptor. In hypertensive mice, anti-Ang II monoclonal antibody significantly promoted coagulation and ameliorated ICH. These results identify Ang II as a key coagulation regulator with heparin-like function, suggesting that targeting Ang II-coagulation pathway could be a novel strategy to mitigate cerebral bleeding.